(Boao, Hainan · November 21, 2025) — Homart Group, representing Australia’s health supplement industry, was officially invited by the Boao Lecheng International Medical Tourism Pilot Zone to attend the Boao Lecheng “Never Ending” International Innovation Drug and Equipment Exhibition. Homart joined global clinical experts and industry leaders on stage to share research insights and present its latest innovations.
Guided by the Hainan Health Commission and the Chinese Pharmaceutical Association, and organized by the Lecheng Administration and the Hainan Institute of Health Industry, the exhibition brought together leading global institutions in innovative drugs, medical devices, medical nutrition, health foods, and life sciences. It is recognized as the most significant international health industry event ahead of the upcoming island-wide customs closure of the Hainan Free Trade Port.
At the exhibition’s key session — the Global Special Medical & Health Foods Sharing Forum — Homart Group Founder & CEO Lynn Yeh delivered a keynote speech as the invited representative of Australian enterprises. She provided a comprehensive overview of the evolution of Australia’s health supplement industry, its scientific research strengths, regulatory framework, and global influence, while presenting Homart’s 34 years of innovation.
In her keynote, Lynn Yeh outlined the three major development stages of Australia’s health industry since the early 20th century — from basic nutritional supplementation, to the rise of herbal and functional nutrition, to Australia becoming a globally recognized provider of high-standard health products. She noted that 14 Nobel Prize laureates have emerged from Australia’s life science fields, creating long-term momentum for innovation. Industry forecasts indicate that Australia’s health and nutrition market is expected to exceed AUD 9.5 billion by 2025, continuing strong global growth.
During the exhibition, Homart showcased several new products, including Thompson’s Milk Thistle 48000 and Brightening Capsules; SpringLeaf High-Strength Fish Oil + Vitamin D and the 7-in-1 Eye Care Capsule; TopLife premium functional nutrition series; and PETMIMA, Australia’s pet nutrition expert (with eight official import approvals issued by China’s Ministry of Agriculture). SpringLeaf has also received five NMPA overseas “Blue Hat” approvals, demonstrating its strong compliance capability in the Chinese market.
Throughout the event, Lynn Yeh was interviewed by CCTV, Hainan TV and China News Service, where she discussed Australia’s global competitiveness in the health industry, the strategic role of Lecheng’s “pilot-first” policy framework, and the international significance of Hainan’s upcoming island-wide customs closure.
Homart is currently applying for 16 core products to enter the Hainan Free Trade Port via the Lecheng Pilot Zone under the Health Food (Pilot) Program, covering sleep support, joint & gout management, beauty & skin health, eye nutrition, anti-fatigue, cardiovascular health, antioxidants, and men’s health — providing Chinese consumers with high-quality, internationally aligned nutrition solutions.
Homart stated that Boao Lecheng serves as a vital gateway for international health products to enter China and a key bridge for Australia–China cooperation in the health industry. The Group will continue leveraging Australia’s strict regulatory standards and scientific expertise to collaborate with Lecheng institutions, accelerating the introduction of high-quality Australian health products to consumers in China and around the world.
